MADISON, Wis.–(BUSINESS WIRE)– Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cell-derived products, today announced it has signed a distribution agreement with STEMCELL Technologies, a world leader in iPS cell culture media.
“This joint agreement with STEMCELL Technologies will make iPSC technology widely available to researchers worldwide, helping advance biological research leading to cellular therapies and drug discovery,” said Dr. Bruce Novich, Division President-CNBD for FUJIFILM Holdings America Corporation and Executive Vice President and General Manager for CDI. “We believe that STEMCELL Technologies, a leading developer, manufacturer and seller of stem cell related products, is an ideal partner for CDI, because their global sales and distribution infrastructure delivers to an established and an emerging customer base, which translates into faster access to and deeper penetration of CDI’s leading edge technologies and products.”
MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. The Opsis Therapeutics team brings deep expertise and a track record of developing breakthrough technologies and building next-generation cell therapeutic programs. The venture has been founded in partnership with David Gamm, M.D., Ph.D., a world leader and pioneer in the differentiation and transplantation of iPSC-derived retinal cells.
MADISON, Wis., September 22, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced the launch of iCell® Hepatoblasts, liver progenitor cells generated from human induced pluripotent stem cells (iPSCs). These cells show promise for liver regeneration therapy research by enabling researchers to identify molecules capable of stimulating liver progenitor cell proliferation and growth. They also provide an in vitro cellular system for studying hepatic development and regeneration and they can be engineered to develop complex liver models for use in in vitro and in vivo applications.
NEW YORK, Sept. 5, 2016 /PRNewswire/ — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016.
MADISON, WIS, September 1, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced that effective September 1, 2016 the company operations will be divided into two equally important business units. Emile Nuwaysir, PhD, President and Chief Operating Officer of CDI, will lead the Therapeutics Business Unit. The Life Science business unit will be led by…
LA JOLLA—The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies will co-lead a $15.4 million effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder, the National Institute of Mental Health (NIMH) has announced. The consortium, which includes four academic or nonprofit institutions and two industry partners, will be led by Hongjun Song, PhD, of Johns Hopkins and Rusty Gage, PhD, of Salk.
MADISON, WIS., June 30, 2016 – Cellular Dynamics International (CDI), a FUJIFILM company, today announced that the company will host the iForum™ 2016 Meeting: US in Philadelphia from Sept. 12-14 and the iForum 2016 Meeting: Europe in Paris on Oct. 11. Annual iForum events provide attendees with a unique opportunity to connect with thought leaders from academia, government, biotech and pharma to discover new applications and uses for differentiated induced pluripotent stem (iPS) cells. The iForum 2016 Meetings will focus on real-life implementation of human iPS cell technologies. The meetings will include scientific talks, poster sessions, small group roundtables and additional networking opportunities.
MADISON, WIS., June 22, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to conduct research to advance a cell transplantation therapy for the treatment of retinal degenerative disease using retinal pigment epithelium derived from induced pluripotent stem cells (iPSC-RPE). The collaboration includes the joint development of an optimized biocompatible biodegradable scaffold that is likely to be acritical component for a potential future therapy.
NEW YORK (May 25, 2016) — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced
funding for two projects leveraging the promise of engineered stem cells to speed new therapies and
deeper understanding of Parkinson’s disease.
MADISON, WIS., May 25, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to derive induced pluripotent stem cells (iPSCs) from 85 people in the MJFF-sponsored Parkinson’s Progression Markers Initiative (PPMI). The collaborators will provide the cells to the scientific community in concert with rich available clinical and imaging data on these study volunteers in service to their shared goal to provide resources to accelerate the development of new therapies.